AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16076378
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g sevelamer hydrochloride + 3 g calcium bicarbonate (CaCO3)
Trial: 16076378
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g calcium bicarbonate (CaCO3) alone
Trial: 12132060
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125% plus sufentanil 0.5 microg/mL
Trial: 10573104
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 30 mg/day orally for 2 years
Trial: 10573104
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 30 mg/day orally for 2 years + UFT 300 mg/day orally for 2 years
Trial: 10573104
Drug: UFT 300
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 300 mg/day orally for 2 years
Trial: 10573104
Drug: UFT 300
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 300 mg/day orally for 2 years + Tamoxifen (TAM) 30 mg/day
Trial: 10573104
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of MMC, TAM, and UFT
Trial: 8692031
Drug: CHO trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO trial (150-g x L(‐1) CHO solution)
Trial: 8692031
Drug: CHO +
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO + MCT trial (70 energy% CHO-30 en% MCT suspension containing 29 g MCT)
Trial: 8692031
Drug: HCHO +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCHO + MCT trial (150-g x L(‐1) CHO solution plus 20 g MCT)
Trial: 1858990
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of atropine and 50 mg of meperidine plus oral placebo (n = 14)
Trial: 1858990
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral diazepam and intramuscular placebo (2 mL NaCl, concentration = 0.9) (n = 14)
Trial: 1858990
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intramuscular placebo (n = 14)
Trial: 6356965
Drug: Budesonide (topically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (topically administered glucocorticoid) for 1 week
Trial: 30914500
Drug: Omega-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA supplementation (1.5 g DHA + 0.3 g EPA/day)
Trial: 30730860
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin alone
Trial: 26941086
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rectal indomethacin and prophylactic pancreatic stent placement (PSP)
Trial: 15506067
Drug: rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine 1 mg bid
Trial: 10865218
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg once a week (weekly alendronate group)
Trial: 10865218
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daily (orally) for 1 month out of 3 (cyclical alendronate group)
Trial: 10865218
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D supplements (control group)
Trial: 9124166
Drug: Sotalol 80
RxNorm normalized name: sotalol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 80 mg twice daily
Trial: 3551508
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg b.i.d.)
Trial: 8228077
Drug: H2-antagonist (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-antagonist (single dose)
Trial: 8228077
Drug: H2-antagonist (14-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-antagonist (14-day chronic dosing)
Trial: 8228077
Drug: H2-antagonist (28-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-antagonist (28-day chronic dosing)
Trial: 3536469
Drug: Vigabatrin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (1.0 g twice daily for patients ≤ 65 kg; 1.5 g twice daily for patients > 65 kg)
Trial: 3042009
Drug: Dithranol +
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithranol + UVB therapy (27 patients)
Trial: 26471852
Drug: Stretching and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching and strengthening exercises plus manual therapy
Trial: 26471852
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (exercise alone and exercise plus manual therapy)
Trial: 23834545
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg kg(‐1))
Trial: 18669012
Drug: Empirically adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirically adjusted doses of LMWH
Trial: 16679545
Drug: 0.2 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg/d sodium selenite in addition to chemotherapy
Trial: 12780888
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem (2%) ointment
Trial: 12780888
Drug: Glyceryltrinitrate (GTN)
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyceryltrinitrate (GTN) (0.5%) ointment
Trial: 9221182
Drug: Consupren at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consupren at an initial dose of 5 mg/kg/d (CS group, n = 16)
Trial: 9221182
Drug: Cyclophosphamide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide at a dose of 1.5 mg/kg/d (K group, n = 11)
Trial: 1587713
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg all‐rac‐alpha‐tocopherol acetate/kg/d intravenously for 5 days
Trial: 2933186
Drug: STK treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STK treatment within 2 hr of onset
Trial: 2933186
Drug: STK treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STK treatment after 2 hr of onset
Trial: 27161257
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg, three times daily)
Trial: 23107220
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin 40 IU q.i.d. (n = 34)
Trial: 17445333
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m2 weekly
Trial: 17445333
Drug: Vinorelbine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 6 mg/m2 weekly
Trial: 12729866
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication (drug trial)
Trial: 10629368
Drug: Induction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of labor using oral prostaglandin E(2) at 37 weeks
Trial: 7902966
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2 out of 3 partial autonomic blockers (indoramin, propranolol, atropine)
Trial: 3710284
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc aspartate application during pregnancy
Trial: 30483715
Drug: Conventional root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional root canal preparation and calcium hydroxide sealant (Control)
Trial: 26065986
Drug: Dabigatran Etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran Etexilate 110 mg
Trial: 26065986
Drug: Dabigatran Etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran Etexilate 150 mg
Trial: 24035168
Drug: niacin-ER (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin-ER (extended-release niacin) at a maximum of 1,500 mg/day for 12 weeks
Trial: 18783622
Drug: RTEC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTEC alone (1 or 2 doses)
Trial: 12553385
Drug: Continuous spinal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous spinal anaesthesia (CSA) with prilocaine 2% 40 mg
Trial: 12553385
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural anaesthesia (CEA) with prilocaine 1% 150 mg
Trial: 18057477
Drug: Phytomenadione (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytomenadione (vitamin K1), 1 mg intramuscularly
Trial: 18057477
Drug: Menadione (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menadione (vitamin K3), 1 mg intramuscularly
Trial: 9602575
Drug: i.v. morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. morphine, i.m. diclofenac and intercostal nerve blocks from T2 to T11, 20 min before operation
Trial: 9602575
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections before operation, and i.v. morphine, i.m. diclofenac and intercostal nerve blocks from T2 to T11 at the end of surgery
Trial: 7767541
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg, four times daily for 16 weeks)
Trial: 7767541
Drug: Albuterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (200 micrograms, four times daily for 16 weeks)
Trial: 2123142
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition with 15 or 30 kcal/kg.day and 0.30 g of N with standard or branch-chain (BC) enriched AA solutions
Trial: 2123142
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition with 30 kcal/kg.day
Trial: 2123142
Drug: BCAA-enriched AA
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA-enriched AA solutions
Trial: 31855097
Drug: Discussion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discussion of risk factors, prevention strategies, and treatment recommendations.
Trial: 25854809
Drug: Home-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based occupational therapy for 10 weeks
Trial: 25854809
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no occupational therapy)
Trial: 25476074
Drug: Furosemide therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide therapy, anisodamine, nitroglycerin, beta blocker or cedilanid
Trial: 22030597
Drug: Triple-combination treatment
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination treatment (olmesartan medoxomil 40/amlodipine besylate 10/hydrochlorothiazide 25 mg)
Trial: 14984936
Drug: Whole pelvic
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole pelvic radiation therapy (RT)
Trial: 14984936
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (NAT)
Trial: 10402973
Drug: SPf66 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 vaccine (three doses at 1, 2, and 7 months of age)
Trial: 2694978
Drug: Thiabendazole 2
RxNorm normalized name: Thiabendazole
DrugBank: Thiabendazole (DB00730)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiabendazole 2 x 25 mg kg‐1 day‐1
Trial: 2694978
Drug: Albendazole 2
RxNorm normalized name: albendazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 2 x 5 mg kg‐1 day‐1
Trial: 973982
Drug: HSA-Tc 99m
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSA-Tc 99m instilled intranasally as spray
Trial: 973982
Drug: HSA-Tc 99m
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSA-Tc 99m instilled intranasally (varied volume 0.10 ml to 0.75 ml, concentration 3% to 30%)
Trial: 973982
Drug: Frequent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent administration by drops
Trial: 28675091
Drug: Coffee polyphenols
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee polyphenols (CPPs) 270 mg/100 mL/day
Trial: 19390480
Drug: 2.7 g
RxNorm normalized name: Magnesium 420 MG/2.7 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.7 g omega-3 LCPUFA supplementation
Trial: 19390480
Drug: 2.8 g
RxNorm normalized name: glycerin 2.8 GM per 2.7 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 g soybean oil as placebo
Trial: 15324779
Drug: Opioid receptor
RxNorm normalized name: Opioid receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid receptor binding in patients with CNP
Trial: 8983932
Drug: Droxicam alone
RxNorm normalized name: droxicam
DrugBank: Droxicam (DB09215)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxicam alone (20 mg)
Trial: 8983932
Drug: Droxicam with
RxNorm normalized name: droxicam
DrugBank: Droxicam (DB09215)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxicam with antacid (Mucal powder)
Trial: 2921100
Drug: Atenolol (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (long-term treatment)
Trial: 27663600
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg twice daily + carboplatin AUC4
Trial: 27663600
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 or 200 mg twice daily (days 1-7) + carboplatin AUC4 or 5 every 21 days
Trial: 19483074
Drug: poly‐L‐lactic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: poly‐L‐lactic acid polymer tack implants
Trial: 19483074
Drug: polygluconate‐B polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polygluconate‐B polymer tack implants
Trial: 19483074
Drug: both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both implant types
Trial: 16508932
Drug: MTX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX plus infliximab (3 mg/kg or 6 mg/kg)
Trial: 11079278
Drug: Metoprolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol plus glucagon 1 mg
Trial: 9522324
Drug: Transdermal 17‐β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17‐β‐estradiol (50 μg/day)
Trial: 26125705
Drug: Zhikang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhikang capsule in addition to conventional dressing changes
Trial: 23418154
Drug: Intermittent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent exercise (INT) - 12 hourly, 5-min bouts
Trial: 14585524
Drug: Estradiol Hemihidrate
RxNorm normalized name: estradiol hemihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol Hemihidrate 2 mg + Norethindron Asetate 1 mg/day
Trial: 14585524
Drug: 17 beta-estradiol
RxNorm normalized name: 17 beta-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta-estradiol 2 mg/day
Trial: 14585524
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pre-therapy values)
Trial: 11872997
Drug: Dronabinol 2.5
RxNorm normalized name: dronabinol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol 2.5 mg capsules
Trial: 10194038
Drug: Intravenous tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tacrolimus followed by oral therapy and mycophenolate mofetil (MMF) with a fixed dose of 2 g/day in Phase I and adjusted doses in Phase II based on mycophenolic acid (MPA) plasma levels.
Trial: 31932567
Drug: Risk factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factors affecting delirium (e.g., age over 65, unconsciousness, dependent activities, abnormal vital signs, pressure ulcer risk, enteral nutrition, use of restraint)
Trial: 23653274
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg fasting and 5 mg at bedtime)
Trial: 23964473
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's Wort extract WS 5570, 600 mg once daily for 8 to 10 weeks
Trial: 23964473
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's Wort extract WS 5570, 600 mg once daily
Trial: 8174440
Drug: Omeprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (60 mg daily)
Trial: 8174440
Drug: Pancreatin monotherapy
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatin monotherapy
Trial: 22318648
Drug: Free consumption
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free consumption of fruits and vegetables (less than 75 mg phenylalanine per 100 g)
Trial: 22318648
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (accounting for protein from fruits and vegetables)
Trial: 16995860
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg twice daily for 6 weeks
Trial: 10750566
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (menatetrenone) 45 mg/day orally
Trial: 10750566
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without treatment)
Trial: 3886024
Drug: L-tryptophan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (12 g/day)
Trial: 3886024
Drug: L-tryptophan (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (continued treatment)
Trial: 3886024
Drug: Placebo (switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (switched from L-tryptophan)
Trial: 3886024
Drug: L-tryptophan (increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (increased synthesis of 5-hydroxytryptamine)
Trial: 3886024
Drug: L-tryptophan (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (in men)
Trial: 3886024
Drug: L-tryptophan (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (in women)
Trial: 26853287
Drug: L-lysine (3
RxNorm normalized name: POLY-L-LYSINE (30000-70000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine (3 g/day)
Trial: 26853287
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and glibenclamide (standard treatment for both groups)
Trial: 25430996
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg testosterone enanthate
Trial: 25430996
Drug: 6.25 mg
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.25 mg testosterone enanthate
Trial: 25430996
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg testosterone enanthate
Trial: 23427401
Drug: Wuziyanzong treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuziyanzong treatment (2.30, 4.60, 9.20 g/kg crude drug) for 30 days
Trial: 18279551
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (50 mg/d)
Trial: 12848775
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m² with Zosuquidar 3HCl
Trial: 12848775
Drug: Paclitaxel 225
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 225 mg/m² with Zosuquidar 3HCl
Trial: 12848775
Drug: Paclitaxel alone
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel alone (175 mg/m² or 225 mg/m²)
Trial: 27568069
Drug: Integrated PTSD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated PTSD and Smoking Treatment (IPST)
Trial: 9657656
Drug: Beta2 agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta2 agonist (salbutamol) inhalation
Trial: 7907871
Drug: Bunazosin retard
RxNorm normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin retard (6 to 18 mg/day)